[go: up one dir, main page]

WO2008109521A3 - Method of treatment using atranorin - Google Patents

Method of treatment using atranorin Download PDF

Info

Publication number
WO2008109521A3
WO2008109521A3 PCT/US2008/055655 US2008055655W WO2008109521A3 WO 2008109521 A3 WO2008109521 A3 WO 2008109521A3 US 2008055655 W US2008055655 W US 2008055655W WO 2008109521 A3 WO2008109521 A3 WO 2008109521A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
closely related
barbatic
related compound
atranorin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/055655
Other languages
French (fr)
Other versions
WO2008109521A2 (en
Inventor
Jun Tan
Roland Douglas Shytle
Demian Obregon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
University of South Florida St Petersburg
Original Assignee
University of South Florida
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida, University of South Florida St Petersburg filed Critical University of South Florida
Publication of WO2008109521A2 publication Critical patent/WO2008109521A2/en
Publication of WO2008109521A3 publication Critical patent/WO2008109521A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/09—Lichens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein is a method of treating a neurodegenerative disease, comprising the step of administering a therapeutically effective amount of Atranorin, or a closely related compound thereof. The neurodegenerative disease is Alzheimer's disease in one embodiment. The closely related compound is selected from the group consisting of chloroatranorin, evernic acid, barbatic acid, 4-O-demethyl-barbatic acid, lecanoric acid, diffratic acid and gyrophoric acid. Also disclosed is a method of treating a cellular proliferative disease, comprising the step of administering a therapeutically effective amount of Atranorin, or a closely related compound thereof. The cellular proliferative disease is cancer in one embodiment. The method of claim 1 wherein the closely related compound is selected from the group consisting of chloroatranorin, evernic acid, barbatic acid, 4-O-demethyl-barbatic acid, lecanoric acid, diffratic acid and gyrophoric acid
PCT/US2008/055655 2007-03-02 2008-03-03 Method of treatment using atranorin Ceased WO2008109521A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89259107P 2007-03-02 2007-03-02
US60/892,591 2007-03-02

Publications (2)

Publication Number Publication Date
WO2008109521A2 WO2008109521A2 (en) 2008-09-12
WO2008109521A3 true WO2008109521A3 (en) 2008-12-24

Family

ID=39739051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055655 Ceased WO2008109521A2 (en) 2007-03-02 2008-03-03 Method of treatment using atranorin

Country Status (1)

Country Link
WO (1) WO2008109521A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2433142B1 (en) * 2012-06-04 2015-01-23 Fundación Medina, Centro De Excelencia En Investigación De Medicamentos Innovadores En Andalucía Use of ortho-depside compounds as neuroprotective agents
TR201514423A3 (en) * 2015-11-16 2017-02-21 Bahadir Sueleyman An extract for the treatment of cancer.
KR102478582B1 (en) 2021-01-25 2022-12-16 부산대학교 산학협력단 Composition for preventing or treating parkinson's disease comprising evernic acid
KR20240006143A (en) 2022-07-06 2024-01-15 (주)피알지에스앤텍 Composition for preventing or treating parkinson's disease comprising novel compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198815A1 (en) * 2003-03-31 2004-10-07 Council Of Scientific And Industrial Research Antimicrobial and anticancer properties of methyl-beta-orcinolcarboxylate from lichen (Everniastrum cirrhatum)
US6927056B2 (en) * 2001-09-06 2005-08-09 Incyte Corporation Proteases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927056B2 (en) * 2001-09-06 2005-08-09 Incyte Corporation Proteases
US20040198815A1 (en) * 2003-03-31 2004-10-07 Council Of Scientific And Industrial Research Antimicrobial and anticancer properties of methyl-beta-orcinolcarboxylate from lichen (Everniastrum cirrhatum)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BEHERA ET AL.: "Evaluation of Antioxidant Potential of the Culture Mycobiont of a Lichen Usnea ghattensis", PHYTOTHERAPY RESEARCH, vol. 19, 2005, pages 59, 61 - 62 *

Also Published As

Publication number Publication date
WO2008109521A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2004068931A3 (en) Amphiregulin antibodies and their use to treat cancer and psoriasis
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2009067397A3 (en) Treatment for solid tumors
WO2006078463A3 (en) Method for treating cardiovascular disease
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
PL1765388T3 (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
WO2005084295A3 (en) Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
WO2004041245A3 (en) Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases
WO2005046661A3 (en) Use of nitric oxide donors for the treatment of drug addiction
WO2009030224A3 (en) Novel quinazoline compounds and the use thereof for treating cancerous diseases
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2010041252A3 (en) Use of a cinnamon bark extract for treating amyloid-associated diseases
WO2006047631A3 (en) Anti-mitotic anti-proliferative compounds
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2006113978A3 (en) Insulins combinations
WO2008109521A3 (en) Method of treatment using atranorin
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2006034512A3 (en) Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2008036733A3 (en) Methods for treatment of vesicle transport disorders
IL167848A (en) Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731245

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08731245

Country of ref document: EP

Kind code of ref document: A2